secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001104659-25-055717
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics launches expanded access program for zervimesine in DLB
------------------------------------------------------------------------------

- Anonymous philanthropic donation from family of DLB patient who was in SHIMMER study funds the program.
- Open-label EAP: 100 mg oral zervimesine daily for ~1 year; targets ~30 patients initially across 8 U.S. sites.
- First site activated: Banner Sun Health Research Institute; Dr. David Shprecher site investigator; Dr. James Galvin lead investigator.
- EAP open to eligible SHIMMER completers and other mild-to-moderate DLB patients meeting criteria.
- Company aims to start providing zervimesine this month (June 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925055717/0001104659-25-055717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925055717/tm2516905d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer